These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35527570)

  • 1. Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms.
    Petricca L; Chiki N; Hanna-El-Daher L; Aeschbach L; Burai R; Stoops E; Fares MB; Lashuel HA
    J Parkinsons Dis; 2022; 12(5):1449-1462. PubMed ID: 35527570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
    Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
    Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.
    Angius F; Mocci I; Ercoli T; Loy F; Fadda L; Palmas MF; Cannas G; Manzin A; Defazio G; Carta AR
    J Neurol; 2023 Nov; 270(11):5613-5621. PubMed ID: 37552278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?
    Mollenhauer B
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S76-9. PubMed ID: 24262194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.
    Oeckl P; Metzger F; Nagl M; von Arnim CA; Halbgebauer S; Steinacker P; Ludolph AC; Otto M
    Mol Cell Proteomics; 2016 Oct; 15(10):3126-3138. PubMed ID: 27507836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson's Disease Patients.
    Youssef P; Kim WS; Halliday GM; Lewis SJG; Dzamko N
    J Parkinsons Dis; 2021; 11(4):1761-1772. PubMed ID: 34151860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.
    Sorrentino ZA; Hass E; Vijayaraghavan N; Gorion KM; Riffe CJ; Dhillon JS; Giasson BI
    Neurosci Lett; 2020 Jul; 732():135017. PubMed ID: 32371157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.
    Kleinknecht A; Popova B; Lázaro DF; Pinho R; Valerius O; Outeiro TF; Braus GH
    PLoS Genet; 2016 Jun; 12(6):e1006098. PubMed ID: 27341336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein.
    Srivastava A; Alam P; Caughey B
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid.
    Shahnawaz M; Tokuda T; Waragai M; Mendez N; Ishii R; Trenkwalder C; Mollenhauer B; Soto C
    JAMA Neurol; 2017 Feb; 74(2):163-172. PubMed ID: 27918765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
    Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
    Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded RT-QuIC Analysis of α-Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients.
    Manne S; Kondru N; Jin H; Serrano GE; Anantharam V; Kanthasamy A; Adler CH; Beach TG; Kanthasamy AG
    Mov Disord; 2020 Dec; 35(12):2230-2239. PubMed ID: 32960470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease.
    Shi J; Wang Y; Chen D; Xu X; Li W; Li K; He J; Su W; Luo Q
    Appl Microbiol Biotechnol; 2023 Mar; 107(5-6):1917-1929. PubMed ID: 36795141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive and specific detection of α-synuclein in human plasma.
    Tinsley RB; Kotschet K; Modesto D; Ng H; Wang Y; Nagley P; Shaw G; Horne MK
    J Neurosci Res; 2010 Sep; 88(12):2693-700. PubMed ID: 20648655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
    Sorrentino ZA; Vijayaraghavan N; Gorion KM; Riffe CJ; Strang KH; Caldwell J; Giasson BI
    J Biol Chem; 2018 Dec; 293(49):18914-18932. PubMed ID: 30327435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding.
    Sorrentino ZA; Xia Y; Gorion KM; Hass E; Giasson BI
    FEBS Lett; 2020 Apr; 594(8):1271-1283. PubMed ID: 31912891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms.
    Winkel I; Ermann N; Żelwetro A; Sambor B; Mroczko B; Kornhuber J; Paradowski B; Lewczuk P
    J Neural Transm (Vienna); 2021 Jun; 128(6):817-825. PubMed ID: 34036433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.
    Bidinosti M; Shimshek DR; Mollenhauer B; Marcellin D; Schweizer T; Lotz GP; Schlossmacher MG; Weiss A
    J Biol Chem; 2012 Sep; 287(40):33691-705. PubMed ID: 22843695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.